2023-09-08 11:59:06 ET
Shares of CymaBay Therapeutics (NASDAQ: CBAY) were jumping 14.2% higher as of 10:54 a.m. ET on Friday. This move came on the heels of an 8.5% gain on Thursday.
The continued momentum is a result of CymaBay's announcement yesterday of positive top-line results from a late-stage clinical study evaluating experimental drug seladelpar in treating primary biliary cholangitis (PBC), a rare chronic inflammatory liver disease.
CymaBay reported that seladelpar achieved the study's primary endpoint as well as all key secondary end points.
For further details see:
Why CymaBay Therapeutics Stock Is Jumping Today